SAB Biotherapeutics Files 8-K on Security Holder Vote Matters

TL;DR

SAB Biotherapeutics is holding a shareholder vote; expect news soon.

AI Summary

SAB Biotherapeutics, Inc. filed an 8-K on June 27, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known as Big Cypress Acquisition Corp., is incorporated in Delaware and is in the biological products industry.

Why It Matters

This filing indicates that SAB Biotherapeutics is seeking approval from its security holders on certain matters, which could impact the company's future strategic decisions and operations.

Risk Assessment

Risk Level: medium — Shareholder votes can lead to significant changes in corporate governance or strategy, introducing uncertainty.

Key Players & Entities

• SAB Biotherapeutics, Inc. (company) — Registrant
• Big Cypress Acquisition Corp. (company) — Former company name
• June 27, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq

Filing Documents

• sabs-20240627.htm (8-K) — 59KB
• 0000950170-24-078622.txt ( ) — 206KB
• sabs-20240627.xsd (EX-101.SCH) — 46KB
• sabs-20240627_htm.xml (XML) — 6KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 27, 2024, SAB Biotherapeutics, Inc., doing business as SAB BIO (the "Company" or "SAB"), held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The total number of shares of common stock entitled to vote at the Annual Meeting was 9,229,208, and there were 6,806,137 shares present in person or by proxy at the Annual Meeting, which represented approximately 73.40% of the outstanding shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction of business. At the Annual Meeting, the shareholders voted to: (1) Elect Samuel J. Reich, Christine Hamilton and Eddie J. Sullivan as Class III directors to serve for a term of three years or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal. (2) Approve an amendment (the "Plan Amendment") to the 2021 Omnibus Equity Incentive Plan (as amended, the "Plan") to, among other things, (i) increase the maximum number of shares of common stock available to Plan participants thereunder by 3,900,000 shares to an aggregate of 5,500,000 shares, and (ii) increase the annual evergreen percentage increase as well as the maximum number of additional shares available for issuance pursuant to the annual evergreen increase. (3) Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. The voting results on these proposals were as follows: Proposal 1 : Election of three Class III directors Director Votes For Withheld Broker Non-Votes Samuel J. Reich 5,080,387 420,707 1,305,043 Christine Hamilton 4,890,928 610,166 1,305,043 Eddie J. Sullivan 5,151,258 349,836 1,305,043 Proposal 2: Approval of Plan Amendment Votes For Votes Against Abstentions Broker Non-Votes 4,172,299 1,325,194 3,60

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: June 27, 2024 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR